MYCN and neoplasm: We additionally predicted the targets of miR-29b with miRanda, TargetScan and PicTar, and finally we found MYCN, a previously reported tumor promoter in glioma carcinogenesis [28, 29], shared the same seed complementarity to MYCN 3′ UTR, which was further validated by luciferase report assay.